AbbVie, Bristol Myers Squibb, Gilead, Merck and other drugmakers are expected on Friday afternoon ​to announce agreements ...

Informing patients about bariatric surgery is a comprehensive discussion, so aim to provide the most up-to-date information about both pre- and post-surgery expectations.

Boehringer Ingelheim has turned down its chance to license Nxera Pharma’s phase 2-ready schizophrenia drug candidate, depriving the Japanese drugmaker of a 60 million euro ($70 million) option payment ...

Nxera Pharma, which recently announced a number of job cuts in Cambridge, is putting on a brave face after suffering another ...

This year, there was a surge of new lung cancer treatments, more options for patients with earlier-stage disease, and growing ...

Sosei Group ( ($JP:4565) ) has provided an announcement. Nxera Pharma will regain full rights to its GPR52 agonist program for schizophrenia, ...

Tokyo, Japan and Cambridge, UK, 19 December 2025 - Nxera Pharma Co. Ltd ('Nxera” or 'the Company; TSE 4565) today announces ...

FDA and European regulators have received tens of thousands of adverse event reports, including seizures and deaths, ...

A generic product for managing pain and inflammation associated with osteoarthritis (OA) in canines has been approved by FDA ...

Feline hyperthyroidism is an endocrine disorder causing an increase in thyroid hormones due to an enlarged thyroid gland in the neck of a cat. It is one of the most commonly diagnosed conditions in ...

The green light for Rybrevant Faspro – which combines amivantamab with hyaluronidase – means that the drug is the first ...

Mepolizumab reduced COPD exacerbations in patients with eosinophilic inflammation, highlighting the potential of ...